TP53 and neoplasm: The presence of MYC or MYCN amplification, along with alterations such as TP53 mutations, MYCL1 amplification (especially in SHH), and mutations in histone methyltransferases like MLL2 and MLL3, is linked to inferior survival, aggressive tumor behavior, and resistance to therapy [111,112,113].